Clinical trials report. Sumatriptan-naproxen combination for symptomatic treatment of comorbid dysmenorrhea and migraine.

摘要

Dysmenorrhea and headache are common menstrual disorders, affecting millions of women worldwide. Both of these conditions are associated with significant disability resulting in work or school absenteeism and substantially impaired quality of life. Migraine is a recurrent headache disorder estimated to affect at least 15% of the population, and is defined as episodic headaches lasting 4 to 72 h, accompanied by photophobia, phonophobia, nausea and vomiting, and restricted activity [1]. The condition is more prevalent in women than in men, with 4 of every 10 women experiencing migraine in their lifetime, most before the age of 35 years [2]. In population-based studies, around 50% of women with migraine report an association between migraine and menstruation [3]. The peak incidence of migraine during the menstrual cycle is on or between 2 days before the onset of menstrual flow and the first 3 days of bleeding [4]. The term menstrual migraine is used to describe attacks that regularly occur at this time [1].